Clinofibrate
featured

    WARNING: This product is for research use only, not for human or veterinary use.

Hodoodo CAT#: H561390

CAS#: 30299-08-2

Description: Clinofibrate is an inhibitor of hydroxymethylglutaryl coenzyme A reductase (HMGCR). Clinofibrate acts as a lipid-lowering agent used for controlling high cholesterol and triacylglyceride levels in the blood.

Chemical Structure

img
Clinofibrate
CAS# 30299-08-2
Instruction

Theoretical Analysis

Hodoodo Cat#: H561390
Name: Clinofibrate
CAS#: 30299-08-2
Chemical Formula: C28H36O6
Exact Mass: 468.25
Molecular Weight: 468.590
Elemental Analysis: C, 71.77; H, 7.74; O, 20.49

Price and Availability

Size Price Availability Quantity
10mg USD 300 2 Weeks
50mg USD 805 2 Weeks
Bulk inquiry

Synonym: Clinofibrate; Lipoclin;

IUPAC/Chemical Name: 2-[4-[1-[4-(2-Carboxybutan-2-yloxy)phenyl]cyclohexyl]phenoxy]-2-methylbutanoic acid

InChi Key: BMOVQUBVGICXQN-UHFFFAOYSA-N

InChi Code: InChI=1S/C28H36O6/c1-5-26(3,24(29)30)33-22-14-10-20(11-15-22)28(18-8-7-9-19-28)21-12-16-23(17-13-21)34-27(4,6-2)25(31)32/h10-17H,5-9,18-19H2,1-4H3,(H,29,30)(H,31,32)

SMILES Code: CCC(C)(OC1=CC=C(C2(C3=CC=C(OC(CC)(C(O)=O)C)C=C3)CCCCC2)C=C1)C(O)=O

Appearance: Solid powder

Purity: >98% (or refer to the Certificate of Analysis)

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility: Soluble in DMSO

Shelf Life: >2 years if stored properly

Drug Formulation: This drug may be formulated in DMSO

Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code: 2934.99.9001

More Info:

Biological target:
In vitro activity:
In vivo activity:

Preparing Stock Solutions

The following data is based on the product molecular weight 468.59 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
Formulation protocol:
In vitro protocol:
In vivo protocol:

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.
=
x
x
g/mol

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.

=
÷

Dilution Calculator

Calculate the dilution required to prepare a stock solution.
x
=
x

1: Li JK, Lu C, Yang J, Li F, Ge J, Wei S, Xueqing L, Ding L, Ai-Dong W. Development of a LC-MS/MS method for the estimation of clinofibrate in human urine. Pharmazie. 2015 Apr;70(4):219-24. PubMed PMID: 26012250.

2: Li JK, Ding LK, Li XQ, Chen MC, Wang L, Yang J, Song Y, Song W, Jia YY, Wen AD. Effect of food on the single-dose pharmacokinetics and tolerability of clinofibrate tablets in Chinese healthy volunteers. Int J Clin Pharmacol Ther. 2013 Aug;51(8):672-7. PubMed PMID: 23849436.

3: Jian-Kang L, Ying S, Lei W, Minchun C, Wei S, Xueqing L, Xiao-Li S, Guangqing L, Yan-Yan J, Ai-Dong W. High-performance liquid chromatographic method for determination of clinofibrate and its application to a pharmacokinetic study in healthy volunteers. J Pharm Biomed Anal. 2013 Mar 25;76:152-6. doi: 10.1016/j.jpba.2012.12.008. Epub 2012 Dec 20. PubMed PMID: 23319135.

4: Fukami T, Takahashi S, Nakagawa N, Maruichi T, Nakajima M, Yokoi T. In vitro evaluation of inhibitory effects of antidiabetic and antihyperlipidemic drugs on human carboxylesterase activities. Drug Metab Dispos. 2010 Dec;38(12):2173-8. doi: 10.1124/dmd.110.034454. Epub 2010 Sep 1. PubMed PMID: 20810539.

5: Shuai J, Liu Y, Liu M, Liu D. 4,4'-(Cyclo-hexane-1,1-di-yl)diphenol methanol solvate. Acta Crystallogr Sect E Struct Rep Online. 2009 Jan 10;65(Pt 2):o269. doi: 10.1107/S1600536809000427. PubMed PMID: 21581883; PubMed Central PMCID: PMC2968192.

6: Tomiyama N, Yasuda N, Iwano C, Matzno S, Matsuyama K. Flow cytometric evaluation of synergistic pro-apoptotic effects of statins and clofibrates in IM-9 human lymphoblasts. Clin Exp Pharmacol Physiol. 2007 Sep;34(9):876-80. PubMed PMID: 17645633.

7: Shiina Y, Homma Y, Oguma T, Fusegawa Y, Ozawa H, Handa S, Tanabe T. A case of familial hypercholesterolemia; secession from LDL-apheresis by the drug treatment with potent statin and resin. Tokai J Exp Clin Med. 2005 Sep;30(3):149-55. PubMed PMID: 16285605.

8: Sato I, Hyakuta M, Hayashi F, Mukai M, Kondo S, Maeda E, Kumagai S. [Usefulness of examination of the cholesterol versus triglyceride ratio for lipoprotein fractions in a patient with marked hyper-triglyceridemia]. Rinsho Byori. 2002 Oct;50(10):987-91. Japanese. PubMed PMID: 12451680.

9: Hayashi K. Influence of fibrates on ethanol metabolism in rats. Nihon Arukoru Yakubutsu Igakkai Zasshi. 2000 Oct;35(5):306-20. PubMed PMID: 11144151.

10: Nishizawa Y, Shoji T, Tabata T, Inoue T, Morii H. Effects of lipid-lowering drugs on intermediate-density lipoprotein in uremic patients. Kidney Int Suppl. 1999 Jul;71:S134-6. PubMed PMID: 10412757.

11: Matsuura K, Hara A, Kato M, Deyashiki Y, Miyabe Y, Ishikura S, Sugiyama T, Katagiri Y. Activation of human liver 3alpha-hydroxysteroid dehydrogenase by clofibrate derivatives. J Pharmacol Exp Ther. 1998 Jun;285(3):1096-103. PubMed PMID: 9618412.

12: Sakuma N, Iwata S, Ikeuchi R, Ichikawa T, Hibino T, Kamiya Y, Ohte N, Kawaguchi M, Kunimatsu M, Kawahara H, et al. Coexisting type III hyperlipoproteinemia and familial hypercholesterolemia: a case report. Metabolism. 1995 Apr;44(4):460-5. PubMed PMID: 7723668.

13: Okazaki M, Zhang H, Ichino K, Amamiya M, Nakayama S, Oguchi K. Effects of clinofibrate on plasma fibrinogen level in high fructose diet-induced hyperlipidemic rats. In Vivo. 1994 Nov-Dec;8(6):1057-61. PubMed PMID: 7772737.

14: Imasaka S, Nakayama S, Oguchi K. [Changes of lipids and lipoproteins in cholesterol free-high fructose diet-fed rats and the effects of clinofibrate]. Nihon Yakurigaku Zasshi. 1994 Feb;103(2):67-78. Japanese. PubMed PMID: 8112691.

15: Nishizawa Y, Shoji T, Nishitani H, Yamakawa M, Konishi T, Kawasaki K, Morii H. Hypertriglyceridemia and lowered apolipoprotein C-II/C-III ratio in uremia: effect of a fibric acid, clinofibrate. Kidney Int. 1993 Dec;44(6):1352-9. PubMed PMID: 8301936.

16: Mizuguchi K, Yano T, Kojima M, Tanaka Y, Ishibashi M, Masada A, Sato M, Mizota M, Fukutake K, Saito Y. Hypolipidemic effect of ethyl all-cis-5,8,11,14,17-eicosapentaenoate (EPA-E) in rats. Jpn J Pharmacol. 1992 Jul;59(3):307-12. PubMed PMID: 1434127.

17: Maruno H, Shimizu T, Kawai K, Hirohata K. The response of osteocytes to a lipid clearing agent in steroid-treated rabbits. J Bone Joint Surg Br. 1991 Nov;73(6):911-5. PubMed PMID: 1955435.

18: Horio T, Kohno M, Murakawa K, Yasunari K, Yokokawa K, Ueda M, Takeda T. Increased plasma immunoreactive endothelin-1 concentration in hypercholesterolemic rats. Atherosclerosis. 1991 Aug;89(2-3):239-46. PubMed PMID: 1793451.

19: McTavish D, Sorkin EM. Pravastatin. A review of its pharmacological properties and therapeutic potential in hypercholesterolaemia. Drugs. 1991 Jul;42(1):65-89. Review. Erratum in: Drugs 1991 Dec;42(6):944. PubMed PMID: 1718686.

20: Suzaki K, Kobori S, Ueno S, Uehara M, Kayashima T, Takeda H, Fukuda S, Takahashi K, Nakamura N, Uzawa H, et al. Effects of plasmapheresis on familial type III hyperlipoproteinemia associated with glomerular lipidosis, nephrotic syndrome and diabetes mellitus. Atherosclerosis. 1990 Jan;80(3):181-9. PubMed PMID: 2310424.